Switch View
© Globe Newswire
19.09.2025
ISIN: US88165K1016
Tevogen Bio Holdings Inc.
TVGN
LISTED
NASDAQ
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
News Preview
WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and rese...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Tempus AI, Inc. (NASDAQ: TEM) breached their fiduciary duties to shareholders. ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: CA98421R1055
XPhyto Therapeutics Corp.
XPHY
LISTED
CSE
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch, CEO of Power Metallic Mines Inc. (TSX-V: PNPN), will continue his role as a capital markets advisor to the Company. Mr. Lynch brings decades of early-s...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
19.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASDAQ: SMLR) between March 10, 2021 and April 15, 2025, both dates inclu...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
19.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusi...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US2825591033
89Bio, Inc.
ETNB
LISTED
NASDAQ
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Transaction in Own Shares
News Preview
For immediate release19 September 2025 WORLDWIDE HEALTHCARE TRUST PLC(the "Company") MARKET PURCHASE OF COMPANY'S OWN SHARES This notification is given, pursuant to the authority granted at an Annual General Meeting of the Company held on 9 July 2025 to make market purchases of the Company's own shares up to an aggregate maximum of 69,602,221...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US8292141053
Simulations Plus Inc
SLP
LISTED
NASDAQ
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: CA68237C1059
Onco-Innovations Limited
ONCO
LISTED
CSE
Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / Onco-Innovations Limited (CBOE CA:ONCO )(OTCQB:ONNVF )(Frankfurt:W1H) (WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to announce that Dalton Pharma Services ("Dalton") has commenced activities to manufacture Onco's proprietary nanoparticle formulation, als...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: JP3701000006
JCR Pharmaceuticals Co., Ltd.
45520
LISTED
XJPX
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
News Preview
JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has achieved a key research milestone in collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”), focused on applying JCR’s proprietary J-Brain Cargo® technology to develop a therap...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: US60770K1079
Moderna, Inc
MRNA
LISTED
NASDAQ
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
News Preview
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone advances Canada's domestic vaccine production capacity and strengthens national health security."The delivery of the first made-in-Canada mRNA va...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
19.09.2025
ISIN: DE0005227235
Biotest AG
BIO3
LISTED
XETR
Einberufung einer außerordentlichen Haupt-versammlung auf Verlangen der Grifols S.A.
News Preview
PRESSEMITTEILUNG
Biotest AG: Einberufung einer außerordentlichen Haupt-versammlung auf Verlangen der Grifols S.A.
Beschlussfassung über den Formwechsel in eine Kommanditgesellschaft auf Aktien (KGaA)
Dreieich, 19. September 2025. Die Biotest AG gibt bekannt, dass der Vorstand nach sorgfältiger Prüfung das am 1. August 2025 schriftlich ei......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.09.2025
ISIN: DE0005227235
Biotest AG
BIO3
LISTED
XETR
Extraordinary general meeting convened at the request of Grifols S.A.
News Preview
PRESS RELEASE
Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A.
Resolution on the change of legal form to a partnership limited by shares (KGaA)
Dreieich, 19 September 2025. Biotest AG announces that, after careful consideration, the Management Board has deemed admissible the request received in writing fro......
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US0028241000
Abbott Laboratories
ABT
LISTED
NYSE
Abbott Declares 407th Consecutive Quarterly Dividend
News Preview
ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
This marks the 407th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 17, 2025, to shareholders of record at the close of business on Oct...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class Action - REPL
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit.
CLASS DEFINITION: The la...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
RxSight, Inc. Class Action: Levi & Korsinsky Reminds RxSight, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - RXST
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to r...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Shareholders that lost money on Alto Neuroscience, Inc.(ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.
CLASS DEFINITION: The...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US02155H2004
Altimmune Inc
ALT
LISTED
NASDAQ
October 6, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to reco...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US90466Y1038
Unicycive Therapeutics, Inc.
UNCY
LISTED
NASDAQ
Shareholders that lost money on Unicycive Therapeutics, Inc.(UNCY) should contact Levi & Korsinsky about pending Class Action - UNCY
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit.
CLASS DEFI...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
Levi & Korsinsky Reminds LifeMD, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 25, 2025 - LFMD
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in LifeMD, Inc. ("LifeMD, Inc." or the "Company") (NASDAQ: LFMD) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to rec...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2025 in Semler Scientific, Inc. Lawsuit - SMLR
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Semler Scientific, Inc. ("Semler Scientific, Inc." or the "Company") (NASDAQ: SMLR) of a class action securities lawsuit.
CLASS DEFINITION: Th...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit.
CLASS DEFINITION: The lawsui...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Investors who lost money on Savara Inc.(SVRA) should contact Levi & Korsinsky about pending Class Action - SVRA
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recov...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Levi & Korsinsky Reminds Lantheus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 10, 2025 - LNTH
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman
News Preview
SAN FRANCISCO, Sept. 19, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease ("ILD"), did not meet its main goal...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC LEI: 5493003YBCY4W1IMJU04 NET ASSET VALUE The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for Worldwide Healthcare Trust PLC at the close of business on 18 September 2025 was 353.66p (cum income). For and on behalf of the B...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Nutex Health (NUTX) Securities Suit Alleges Fraud and Financial Misstatements-- Hagens Berman
News Preview
NUTX Investors with Losses Encouraged to Contact Hagens Berman
SAN FRANCISCO, Sept. 19, 2025 /PRNewswire/ -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to a...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
News Preview
100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in updated results from the Phase 2 MajesTEC-5 study
TORONTO, Sept. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: IE00BTN1Y115
Medtronic PLC
MDT
LISTED
NYSE
Medtronic secures FDA approval for the Altaviva™ device, a simple experience for treating urge urinary incontinence
News Preview
The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks
GALWAY, Ireland, Sept. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today that it has received U.S. Food and Drug Administration (FD...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2025
ISIN: CA46604F1099
Izotropic Corporation
IZO
LISTED
CSE
Izotropic Closes Non-Brokered Private Placement and Engages Awareness Consultants
News Preview
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - September 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2025
ISIN: US29415V1098
Envoy Medical, Inc.
COCH
LISTED
NASDAQ
Envoy Medical Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology
News Preview
Patent covers advanced signal processing for middle ear sensors, further advancing the Company's position in leveraging the ear for fully implanted hearing devicesWhite Bear Lake, Minnesota--(Newsfile Corp. - September 19, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, f...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: CNE100003N76
Shanghai Henlius Biotech, Inc.
2696
LISTED
HKSE
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
News Preview
SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEV...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2025
ISIN: US68764Y2072
OS Therapies, Inc
OSTX
LISTED
XASE
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
News Preview
New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has been invited to participate in the "Beyond the Cure: The Brave New World of Revolutionary Cancer T...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US67080N1019
Nuvation Bio Inc
NUVB
LISTED
NYSE
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZITM (taletrectinib) for the treatment of adult patients with ROS1-positive (ROS1+) unresectable, advanced and/or recurrent n...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2025
ISIN: AU0000317281
Percheron Therapeutics Limited
PER
LISTED
ASX
Edison Issues Report on Percheron Therapeutics (PER)
News Preview
London, United Kingdom--(Newsfile Corp. - September 19, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER).Percheron Therapeutics is an emerging immuno-oncology-focused biotech with a business case anchored on its recent in-licensing of HMBD-002, a Phase II-ready, potentially first-in-class anti-VISTA immune checkpoint inhibitor. HMB...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US4220091007
Healthcare Integrated Technologies, Inc.
HITC
LISTED
OTC
Signature HealthCARE Committed to Proactive Resident Safety with SafeSpace Global Corporation
News Preview
Knoxville, TN, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID:SSGC), a global leader in multimodal AI technology, is pleased to announce an expanded partnership with Signature HealthCARE. Signature HealthCARE, a family-based healthcare company known for delivering integrated care across multiple states and advancing person...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US83548R3030
Sonnet BioTherapeutics Holdings, Inc.
SONN
LISTED
NASDAQ
Sonnet to Present at the MedInvest Biotech & Pharma Conference
News Preview
Live webcast presentation on Thursday, September 25th at 9:40 AM PT Live webcast presentation on Thursday, September 25th at 9:40 AM PT...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US91307C1027
United Therapeutics Corp
UTHR
LISTED
NASDAQ
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
News Preview
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time.
During t...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US4834971032
Kalvista Pharmaceuticals Inc
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the European Commission (EC) and Swiss Agency for Therapeutic Products, Swissmedic, have approved EKTERLY® (sebetralstat), a novel, oral plasma kallikrein inhibitor, for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 year...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: CA1380357048
Canopy Growth Corp
CGC
LISTED
NASDAQ
Canopy Growth Urges Shareholders to Cast their Vote for the Upcoming Annual General and Special Meeting Today
News Preview
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) today urges its shareholders to vote ahead of the upcoming annual general and special meeting of shareholders (the “Meeting”) on September 26, 2025 at 1:00 PM ET.
Canopy Needs Your Vote – Vote Today and Help Us Reach Quorum
Canopy Growth is approaching number o...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: CA24874B1085
dentalcorp Holdings Ltd.
DNTL
LISTED
TSX
Dentalcorp Declares Dividend and Announces Release Date for Third Quarter 2025 Results
News Preview
dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL), Canada’s largest and one of North America’s fastest growing networks of dental practices, declared a dividend and announced that it will release its third quarter 2025 financial results before the market open on November 6, 2025.
Dividend
The Company’s Board of Directors has...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: CA60255C8850
Mind Medicine (MindMed) Inc
MNMD
LISTED
NASDAQ
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
News Preview
Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented results from a cross-sectional retrospective study of more than 75,000 respondents from the 2022 National Health and Wellnes...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US4622221004
Ionis Pharmaceuticals Inc
IONS
LISTED
NASDAQ
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The approval follows the positive opinion of the Committee for Medicinal Products f...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the call at http://inves...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of ENFLONSIA™ (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newb...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US29089Q1058
Emergent BioSolutions Inc
EBS
LISTED
NYSE
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
News Preview
GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29 million (USD). The orders span several product offerings within Emergent’s medical countermeasures (MCM) busines...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
News Preview
Basel, 19 September - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a subcutaneous (SC) formulation of Lunsumio® (mosunetuzumab) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
News Preview
SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announ...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.09.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
News Preview
Berlin, 19 September 2025. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, has received marketing authorization in Japan from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its GalliaPharm® 68Ge/68Ga Radionuclide Generator, t......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.09.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler erhält Zulassung für GalliaPharm® in Japan
News Preview
Berlin, 19. September 2025. Die Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), ein führender Anbieter von Isotopentechnologie für die Nuklearmedizin und radiopharmazeutische Anwendungen, hat von Japans Ministerium für Gesundheit, Arbeit und Soziales (MHLW) die Marktzulassung für den GalliaPharm® 68Ge/68Ga-Radionuklidgenerator erhalte......
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US92511W1080
Verrica Pharmaceuticals Inc
VRCA
LISTED
NASDAQ
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
News Preview
– Approval triggers $10 million cash milestone payment to Verrica –...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US92243A2006
Vaxart Inc
VXRT
LISTED
NASDAQ
Vaxart Announces Withdrawal of Reverse Stock Split Proposal
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it has withdrawn its reverse stock split proposal....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: IE00BF3W0Q35
Iterum Therapeutics Plc
ITRM
LISTED
NASDAQ
Iterum Therapeutics Provides Business Update
News Preview
DUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a general business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US84757T1051
Spectral AI, Inc.
MDAI
LISTED
NASDAQ
Spectral AI Named to TIME’s List of World’s Top HealthTech Companies 2025
News Preview
DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been named to TIME’s World’s Top HealthTech Companies 2025 list. The ranking, re...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US29664W1053
Esperion Therapeutics Inc
ESPR
LISTED
NASDAQ
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
News Preview
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US82835W1080
ARS Pharmaceuticals Inc
SBTX
LISTED
NASDAQ
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
News Preview
neffy 1 mg and 2 mg doses approved by Japanese regulators...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CA48213Y1079
Jushi Holdings Inc.
JUSH
LISTED
CSE
Jushi Holdings Inc. Announces Grand Opening of Beyond Hello™ Parma in Ohio, Expanding its Statewide Retail Footprint
News Preview
A Media Snippet accompanying this announcement is available by clicking on this link....
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US68622V1061
Organon & Co
OGN
LISTED
NYSE
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
News Preview
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the referenc...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
